CORT - Truist upgrades Corcept to buy cites market potential for relacorilant
2023-11-06 16:06:39 ET
More on Corcept Therapeutics
- Corcept Therapeutics Incorporated (CORT) Q3 2023 Earnings Call Transcript
- Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade)
- Corcept Therapeutics Q3 2023 Earnings Preview
- Corcept Therapeutics plunges amid patent trial with Teva (update)
- Seeking Alpha’s Quant Rating on Corcept Therapeutics
For further details see:
Truist upgrades Corcept to buy, cites market potential for relacorilant